Czech ice hockey clubs are in advanced discussions to sign a Swedish forward, rumored to be recovering from a rare but treatable cardiac condition—specifically, a hypertrophic cardiomyopathy (HCM) variant linked to a genetic MYH7 mutation. The player’s eligibility hinges on whether his condition meets European Sports Safety Federation (ESSF) criteria for competitive play, a decision that could set a precedent for athletes with inherited cardiomyopathies across the continent. The stakes are high: HCM affects 1 in 500 people globally, yet only 5% of cases are diagnosed before symptoms emerge.
This situation forces a critical question: How should sports medicine reconcile evidence-based cardiac risk stratification with the physical demands of elite athletics? The answer lies in integrating genetic screening, echocardiography, and longitudinal monitoring—standards already mandated in the NHL but still evolving in Europe. For patients and athletes alike, the implications extend far beyond the rink.
In Plain English: The Clinical Takeaway
- HCM is a genetic heart condition where the heart muscle thickens abnormally, increasing the risk of arrhythmias or sudden cardiac death—but it’s often manageable with medication, lifestyle changes, or, in severe cases, an implantable defibrillator.
- Not all HCM cases are equal: Some variants (like the MYH7 mutation) may carry higher risk, but others can be low-risk with proper monitoring. A single ECG isn’t enough; genetic testing and stress tests are key.
- Elite athletes with HCM can compete—but with strict protocols. The NHL requires annual cardiac screening for all players; Europe’s ESSF is catching up, but guidelines vary by country.
The Cardiac Condition: Hypertrophic Cardiomyopathy (HCM) and Athletic Eligibility
The Swedish forward in question is reportedly carrying a MYH7 mutation, which encodes the beta-myosin heavy chain—a protein critical for cardiac muscle contraction. When mutated, it leads to disorganized sarcomere (heart muscle fiber) structure, impairing diastolic filling and predisposing to ventricular arrhythmias (irregular heartbeats). The condition is highly penetrant (meaning nearly all mutation carriers will develop HCM) but exhibits variable expressivity: some athletes may remain asymptomatic for decades, while others face life-threatening complications.
Diagnosis relies on a multimodal approach:
- Echocardiography: Ultrasound imaging to measure left ventricular wall thickness (a hallmark of HCM). Thickness ≥15mm in adults raises red flags.
- Cardiac MRI: Provides detailed tissue characterization, detecting fibrosis (scar tissue) that correlates with arrhythmic risk.
- Genetic testing: Identifies mutations like MYH7 or MYBPC3, though 30% of HCM cases lack a identifiable genetic cause (idiopathic).
- Holter monitor: 24–48-hour ECG to capture intermittent arrhythmias.
The player’s case mirrors a 2024 JAMA Cardiology study of 1,200 athletes with HCM, where 12% experienced sudden cardiac events—primarily in those with septal thickness >22mm or a family history of sudden death. The study underscored that symptom-free athletes are not risk-free; asymptomatic HCM accounts for 20% of sudden deaths in young athletes.
In Plain English: The Clinical Takeaway (Part 2)
- Thickened heart walls ≠ automatic disqualification. The ESSF’s 2025 guidelines allow competition if wall thickness is <19mm and no arrhythmias are detected on Holter monitoring.
- Genetic testing isn’t a crystal ball. A MYH7 mutation doesn’t doom an athlete—it’s a risk factor, not a death sentence.
- Monitoring is non-negotiable. Even cleared athletes must undergo annual screenings, including stress tests to simulate game-day demands.
Regulatory Mismatch: NHL vs. Europe’s Patchwork Approach
While the NHL’s Pre-Participation Cardiovascular Screening Program mandates annual echocardiograms for all players, Europe’s approach is fragmented. The Czech Republic’s Český lékařský komora (Czech Medical Chamber) aligns with the European Society of Cardiology (ESC) guidelines, which recommend risk stratification but leave eligibility decisions to individual clubs—a system critics call “medically inconsistent.”
A 2023 European Heart Journal analysis found that 68% of European leagues lack standardized HCM protocols, compared to 100% compliance in the NHL. This disparity raises concerns about legal liability (e.g., a Czech club could face lawsuits if a player with undiagnosed HCM collapses) and player safety.
“The NHL’s model is the gold standard, but Europe’s decentralized healthcare systems make uniform adoption difficult,” says Dr. Lars Svensson, cardiologist at Karolinska Institutet and lead author of the ESC’s 2024 HCM guidelines. “We’re pushing for a pan-European cardiac registry to track outcomes, but until then, clubs must err on the side of caution—especially for genetic variants like MYH7.”
The Swedish player’s case could accelerate change. If cleared, it would validate Europe’s emerging “shared decision-making” model, where athletes, doctors, and clubs collaborate on risk-benefit analyses. However, without a centralized database, clubs risk relying on anecdotal rather than evidence-based thresholds.
Funding and Bias: Who Stands to Gain?
The underlying research on MYH7-related HCM was primarily funded by:
- The Swedish Heart-Lung Foundation (independent, patient advocacy-driven).
- The European Union’s Horizon Europe program (via the CardioGenes consortium, studying genetic cardiomyopathies).
- Boston Scientific (manufacturer of implantable defibrillators), which co-sponsored a 2025 Circulation study on HCM management—but disclosed no conflicts in the trial design.
Critics note that device-based solutions (like ICDs) may be overemphasized in industry-funded studies, though the MYH7 research itself remains independent. The CardioGenes consortium’s work is peer-reviewed and open-access, mitigating bias risks.
Data: HCM in Athletes—Risk Stratification by Severity
| Risk Category | Key Features | Competitive Play Eligibility (ESSF 2025) | 5-Year Event-Free Survival Rate |
|---|---|---|---|
| Low Risk | Wall thickness <19mm, no arrhythmias, no family history of SCD | Allowed with annual monitoring | 98% |
| Moderate Risk | Wall thickness 19–22mm, non-sustained VT on Holter, or MYH7 mutation | Allowed if ICD implanted and club agrees to emergency protocols | 92% |
| High Risk | Wall thickness >22mm, sustained VT, or prior syncope | Disqualified unless experimental therapies (e.g., myectomy) reduce risk | 75% |
Contraindications & When to Consult a Doctor
While HCM is manageable for many athletes, certain red flags demand immediate medical evaluation:
- Symptoms of heart failure: Shortness of breath during exertion, fatigue, or swelling in the legs (edema), which may indicate diastolic dysfunction.
- Arrhythmias: Palpitations, dizziness, or fainting (syncope), especially if linked to exertion.
- Family history: A first-degree relative (parent/sibling) who died suddenly before age 50 or was diagnosed with HCM.
- Abnormal ECG: Even if asymptomatic, a non-specific ST-T wave abnormality warrants further workup.
For athletes already diagnosed with HCM:
- Consult a sports cardiologist before returning to competition.
- Carry an ICD if classified as moderate/high risk.
- Avoid competitive sports with high adrenergic stress (e.g., ice hockey, soccer) unless cleared by a specialist.
The Future: Toward a Unified European Standard
The Swedish player’s potential signing could catalyze change, but challenges remain. The European Society of Cardiology is piloting a digital twin model to simulate individual HCM progression, though adoption hinges on funding and political will. Meanwhile, the Czech Republic’s Ministry of Health is reviewing whether to mandate pre-participation screenings for professional athletes—a move that could reduce the diagnostic lag seen in Europe.
For now, the onus is on clubs to prioritize proactive over reactive care. As Dr. Svensson notes, “The goal isn’t to ban athletes with HCM—it’s to ensure they’re not the next statistic.” With 1 in 500 people carrying the genetic risk, the conversation isn’t just about one player—it’s about redefining what “safe” means in sports medicine.
References
- Maron et al. (2024). “Hypertrophic Cardiomyopathy in Athletes: JAMA Cardiology.”
- O’Mahony et al. (2025). “Risk Stratification in Genetic Cardiomyopathies: Circulation.”
- European Society of Cardiology (2025). “Guidelines on the Management of Hypertrophic Cardiomyopathy.”
- WHO (2023). “Global Atlas of Cardiovascular Disease Risk.”
- NHL (2024). “Updated Cardiac Screening Protocols.”
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for diagnosis or treatment.
